DailyIQ
|
Sector:TechnologyAll sectors
Last updated 2 days ago

ALAB·ALAB

$.
+. (+.%)
After Hours
High
$133.29
Open
$128.24
Market Cap
21.84B
52W High
$262.90
Low
$122.57
P. Close
$287.57
P/E
109.84
52W Low
$47.12
Fwd P/E
-
Mean Target
$204.47
Technical Score (1D)
23
SELL
News Sentiment
61
BULLISH
Solid Biosciences (ALAB) is navigating a pivotal moment. The company announced alignment with the FDA on a registration pathway for SGT-003, a move that supports the potential for accelerated approval. This development could significantly impact ALAB's valuation, as successful trials could lead to faster market entry. The company also reported promising early signals from a Friedreich’s ataxia trial, which has prompted further patient enrollment. This suggests potential expansion of ALAB's therapeutic focus. Investors should watch for updates on the DMD study and further data from the Friedreich’s ataxia trial, as these will be key drivers of future performance.
Earnings Summary
Astera Labs, Inc. designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure, operating within the technology sector, specifically the semiconductors industry. In the most recent quarters, ALAB's performance shows a strong upward trend. Q4 2024 saw an EPS of $0.37 on revenue of $141.1 million, while Q4 2025 reported an EPS of $0.58 on revenue of $270.6 million. The company beat estimates in Q4 2024 and Q4 2025, demonstrating consistent growth. Examining the historical trajectory, ALAB has shown significant year-over-year revenue growth, driven by the expansion of AI infrastructure. The company has consistently exceeded revenue expectations, indicating strong market demand. Recent news indicates that despite exceeding Q4 earnings and revenue expectations, the market reacted negatively, likely due to concerns about margin pressure, rising expenses, and the CFO transition. Investors should watch for the impact of the CFO transition and the company's strategic initiatives on future earnings. Key will be the company's ability to manage costs and capitalize on the growing demand for AI infrastructure.

EPS

EstBeatMiss
$0.21$0.32$0.43$0.55$0.66Q4'24Q4'25Q1'26
QtrEstActual+/−
Q1'26$0.55$0.61+11.6%
Q4'25$0.52$0.58+11.1%
Q4'24$0.26$0.37+42.8%

Revenue

EstBeatMiss
$116M$170M$225M$279M$333MQ4'24Q4'25Q1'26
QtrEstActual+/−
Q1'26$298M$308M+3.5%
Q4'25$260M$271M+4.0%
Q4'24 - $141M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ALAB Stock Snapshot

ALAB is currently trading at $293.37, giving ALAB a market cap of 21.84B and a P/E ratio of 109.8. Today's range spans $122.57–$133.29, with shares opening at $128.24 and moving up $5.80 (2.0%) from the prior close. DailyIQ's technical score sits at 23/100 (SELL) with a news sentiment reading of 61/100.

Over the past year ALAB has traded between $47.12 and $262.90 - the current price is +522.6% off the 52-week low and +11.6% from the high. 30 analysts cover the stock with a Buy consensus and a mean 12-month target of $204.47 (range $155.00–$250.00), implying downside of -30.3%.

ALAB (ALAB) is a large-cap in Technology with 21.84B in market cap, and the current technical read is bearish. Score: 23/100 (SELL). Sentiment: bullish at 61/100. Price: $293.37 (near 52-week highs). The current P/E ratio stands at 109.8. The 52-week range of $47.12–$262.90 provides the structural context, and the current SELL designation suggests that prior support levels are more important to watch than usual.

The current SELL phase for ALAB (23/100) at $293.37 (near 52-week highs) suggests that the market is discounting either a fundamental deterioration or a sector headwind that hasn't fully appeared in the earnings line yet. Sentiment at 61/100 (bullish) confirms that news flow is not providing a counternarrative. At 21.84B in Technology capitalization, ALAB has the liquidity for institutional exits to be orderly — but orderly doesn't mean shallow within the $47.12–$262.90 range.